IP Library Granted Patent US 11,118,224
Granted Patent B2
US 11,118,224 · App. 16/896,731 · Granted Sep 14, 2021

Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs

Inventors: Jennifer A. Doudna (Berkeley, CA); Janice S. Chen (Berkeley, CA); Lucas Benjamin Harrington (Berkeley, CA); Enbo Ma (Moraga, CA)
Assignee: The Regents of the University of California
C12Q1/6876C12N9/22C12N15/11C12Q1/6823C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,118,224
App. No.
16/896,731
Granted
Sep 14, 2021
Kind
B2
Abstract

Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a “single stranded detector DNA”) and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell.

Claims (34)

1. A method of assaying for a target nucleic acid in a sample, the method comprising:

a) contacting the sample to a single volume comprising:

i) reagents for amplification;

ii) a type V CRISPR/Cas effector protein;

iii) a guide nucleic acid comprising a nucleotide sequence that hybridizes to a nucleic acid segment of an amplification product of the target nucleic acid; and

iv) a detector DNA molecule;

b) amplifying the target nucleic acid in the single volume; and

c) assaying for a signal produced by cleavage of the detector DNA molecule by the type V CRISPR/Cas effector protein upon hybridization of the guide nucleic acid to the segment of the amplification product of the target nucleic acid in the single volume.

2. The method of claim 1 , wherein the reagents for amplification comprise a primer, a polymerase, or a combination thereof.

3. The method of claim 1 , wherein the amplifying comprises isothermal amplification.

4. The method of claim 1 , wherein the amplifying comprises one or more of: loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), recombinase polymerase amplification (RPA), strand displacement amplification (SDA), nucleic acid sequence-based amplification (NASBA), transcription mediated amplification (TMA), nicking enzyme amplification reaction (NEAR), rolling circle amplification (RCA), multiple displacement amplification (MDA), ramification (RAM), circular helicase-dependent amplification (cHDA), single primer isothermal amplification (SPIA), self-sustained sequence replication (3SR), genome exponential amplification reaction (GEAR), isothermal multiple displacement amplification (IMDA), RNA amplification via T7 promoter, or polymerase chain reaction (PCR).

5. The method of claim 1 , wherein the single volume is incubated at a single temperature.

6. The method of claim 1 , wherein the single volume is incubated from about 37° C. to about 95° C.

7. The method of claim 1 , comprising contacting the sample to reagents for reverse transcription and reverse transcribing the target nucleic acid.

8. The method of claim 1 , wherein the reagents for reverse transcription comprise a reverse transcriptase and Rnase H.

9. The method of claim 1 , wherein the single volume comprises reagents for reverse transcription and the method comprises reverse transcribing the target nucleic acid comprising RNA, amplifying the reverse transcribed target nucleic acid by LAMP, and assaying for the signal upon cleavage of the detector DNA molecule by the type V CRISPR/Cas effector protein.

10. The method of claim 9 , wherein the reagents for reverse transcription are in the single volume.

11. The method of claim 1 , wherein the target nucleic acid is single stranded or double stranded.

12. The method of claim 1 , wherein the target nucleic acid is DNA or RNA.

13. The method of claim 1 , wherein the target nucleic acid is a viral nucleic acid or a bacterial nucleic acid.

14. The method of claim 1 , wherein the target nucleic acid is a papovavirus, a human papillomavirus (HPV), a hepadnavirus, a Hepatitis B Virus (HBV), a herpesvirus, a varicella zoster virus (VZV), an Epstein Barr virus (EBV), a Kaposi's sarcoma-associated herpesvirus, an adenovirus, a poxvirus, a parvovirus, an influenza virus, or a respiratory syncytial virus nucleic acid.

15. The method of claim 1 , wherein the target nucleic acid is from a human cell.

16. The method of claim 1 , wherein the target nucleic acid is a human fetal nucleic acid or a cancer cell nucleic acid.

17. The method of claim 1 , wherein the type V CRISPR/Cas effector protein is a Cas12 protein comprising a Cas12a polypeptide, a Cas12b polypeptide, a Cas12c polypeptide, a Cas12d polypeptide, a Cas12e polypeptide, a C2c4 polypeptide, a C2c8 polypeptide, a C2c5 polypeptide, a C2c10 polypeptide, or a C2c9 polypeptide.

18. The method of claim 1 , wherein the sample comprises a cell or a cell lysate.

19. The method of claim 1 , wherein the sample is blood, saliva, biopsy, plasma, serum, bronchoalveolar lavage, sputum, a fecal sample, cerebrospinal fluid, a fine needle aspirate, a buccal swab, a cervical swab, a nasal swab, interstitial fluid, synovial fluid, nasal discharge, tears, buffy coat, or a mucous membrane sample.

20. The method of claim 1 , comprising determining an amount of the target nucleic acid.

21. The method of claim 1 , wherein the assaying for the signal produced by cleavage of the detector DNA molecule comprises one or more of: visual based detection, sensor based detection, color detection, gold nanoparticle based detection, fluorescence polarization, colloid phase transition/dispersion, electrochemical detection, and semiconductor-based sensing.

22. The method of claim 1 , wherein the detector DNA molecule produces the signal prior to cleavage of the detector DNA molecule, and the signal is reduced after cleavage of the detector DNA molecule.

23. The method of claim 1 , wherein the signal increases after cleavage of the detector DNA molecule.

24. The method of claim 1 , wherein the detector DNA molecule comprises one or more fluorescence-emitting dye pairs.

25. The method of claim 24 , wherein the one or more fluorescence-emitting dye pairs includes a fluorescence resonance energy transfer (FRET) pair, a quencher and fluorophore pair, or a combination thereof.

26. The method of claim 1 , wherein the detector DNA molecule comprises a modified nucleobase, a modified sugar moiety, a modified nucleic acid linkage, or a combination thereof.

27. The method of claim 1 , wherein the guide nucleic acid comprises a constant region comprising the nucleotide sequence set forth in SEQ ID NO:11.

Assignments (6)
CONFIRMATORY LICENSE Recorded Feb 5, 2025
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 070111/0969 →
CORRECTION BY DECLARATION TO CORRECT CONVEYANCE AND DOCUMENTS ERRONEOUSLY FILED AT 055223/0805 Recorded Sep 19, 2023
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064953/0485 →
CORRECTION BY DECLARATION TO CORRECT CONVEYANCE AND DOCUMENTS ERRONEOUSLY FILED AT 057525/0141 Recorded Sep 19, 2023
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064953/0509 →
CORRECTIVE BY NULLIFICATION TO CORRECT INCORRECTLY RECORDED APPLICATION/PATENT NUMBERS (SEE ATTACHMENT) AT REEL/FRAME 055223/0805. ASSIGNOR HEREBY CONFIRMS THE CHANGE OF ADDRESS. Recorded Sep 16, 2021
From: MAMMOTH BIOSCIENCES, INC.
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 057525/0141 →
CHANGE OF ADDRESS OF THE ASSIGNEE Recorded Feb 4, 2021
From: MAMMOTH BIOSCIENCES, INC.
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 055223/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: DOUDNA, JENNIFER A.; CHEN, JANICE S.; HARRINGTON, LUCAS BENJAMIN; MA, ENBO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 054958/0199 →